Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25671 | 0.81 | — | — | |
| SCHEMBL15448547 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL4425049 | 0.79 | — | — | |
| Water SCHEMBL15879966 | 0.79 | — | — | |
| SCHEMBL19088381 | 0.77 | MEN1 (0.32) | MEN1CYP2C9KMT2A | |
| SCHEMBL471835 | 0.77 | CYP2C19 (0.34) | — | |
| SCHEMBL8768141 | 0.77 | — | — | |
| SCHEMBL648973 | 0.75 | CYP2C19 (0.38) | MEN1KMT2A | |
| Vinyl Chloride SCHEMBL2308804 | 0.75 | FFAR3 (0.31) | — | |
| Acrylic Acid SCHEMBL1652920 | 0.75 | LMNA (0.50) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243219-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | CYPRALIS LIMITED (GB) | 2025-07-31 | — | — | US | disclosed |
| EP-4526308-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | Cypralis Limited (GB) | 2025-03-26 | — | — | EP | disclosed |
| CN-119451968-A | Macrocyclic compounds and uses thereof | 西普拉里斯有限公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2023223057-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | CYPRALIS LIMITED (GB) | 2023-11-23 | — | — | WO | disclosed |
| US-10472392-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| EP-2861601-B1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2018-02-07 | — | — | EP | disclosed |
| US-20170190734-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | Selcia Ltd. (GB) | 2017-07-06 | — | — | US | disclosed |
| US-20170190734-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | Selcia Ltd. (GB) | 2017-07-06 | — | — | US | disclosed |
| US-9642889-B2 | Macrocyclic inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9642889-B2 | Macrocyclic inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160220633-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160220633-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20150361132-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| US-20150361132-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| US-9062092-B2 | Macrocyclic inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062092-B2 | Macrocyclic inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2015-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472392-B2 | Macrocyclic inhibitors of flaviviridae viruses | HAVCR2, ZC3HAV1, HCCS | MEN1 3498/4885CYP2C9 37/4885KMT2A 3798/4885 |
| US-20160220633-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, HCCS | MEN1 3498/4885CYP2C9 37/4885KMT2A 3798/4885 |
| US-20170190734-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, HCCS | MEN1 3498/4885CYP2C9 37/4885KMT2A 3798/4885 |
| US-20150361132-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, HCCS | MEN1 3498/4885CYP2C9 37/4885KMT2A 3798/4885 |
| US-20250243219-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | CASP3, TNNC1, BAD | MEN1 1206/4885CYP2C9 3963/4885KMT2A 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.